Canopy Growth Q2 Earnings Outperform, Stock Surges 7.34% Despite 70% Yearly Decline

Canopy Growth (CGC) reported Q2 fiscal 2026 results that exceeded analyst forecasts, driven by strong momentum in the Canadian adult-use and medical cannabis segments. The company's operational improvements and disciplined cost management helped narrow losses and lift gross margins. Despite persistent supply chain challenges in Europe, Canopy Growth's Canadian operations maintained growth through innovative vape offerings and a steady increase in medical cannabis patients. The stock's outlook now rests on consistent execution of its priorities and continued progress toward stable profitability.